AMLX vs BAC · rev $87.4M vs P/E 13, rev $113.10B
Amylyx Pharmaceuticals Inc (AMLX) versus Bank of America Corp (BAC) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Bank of America Corp (BAC) is a banks - diversified company listed on US. It is led by Brian Moynihan.
Latest reported AMLX revenue for 2024-12-31 was $87.4M. Net income was -$301.7M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AMLX currently screens at market cap $561.6M.
Latest reported BAC revenue for 2025-12-31 was $113.10B. Net income was $30.51B. Revenue was up 11.0% from 2024-12-31 to 2025-12-31. BAC currently screens at market cap $382.01B and trailing P/E 13.4.
AMLX currently screens at market cap $561.6M. BAC currently screens at market cap $382.01B and trailing P/E 13.4.
Not investment advice. Open the AMLX and BAC stock pages for the full models.
Not investment advice.